Cover Image
市場調查報告書

克隆氏症市場·預測分析

Crohn's Disease: Full Disease Coverage

出版商 Datamonitor Healthcare 商品編碼 498956
出版日期 內容資訊 英文 315 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
克隆氏症市場·預測分析 Crohn's Disease: Full Disease Coverage
出版日期: 2017年12月17日 內容資訊: 英文 315 Pages
簡介

本報告提供克隆氏症的已上市藥物及開發平台趨勢,彙整疾病概要,目前治療選擇,未滿足需求,各區各國的診斷患者數的變化與預測,主要的已上市藥物簡介,開發平台趨勢等資料。

治療:克隆氏症

  • 摘要整理
  • 主要調查手法
  • 患者區分
  • 目前治療選擇
  • 處方趨勢
  • 遵守
  • 克隆氏症的未滿足需求
  • 處方的影響因素
  • 生技仿製藥的影響

流行病學:克隆氏症

  • 摘要整理
  • 疾病的背景
  • 資訊來源·調查手法
  • 預測
  • 流行病學者的考察
  • 優勢·規定
  • 附錄

已上市藥物:克隆氏症

  • 摘要整理
  • 產品概要
  • 產品簡介:Cimzia
  • 產品簡介:Entyvio
  • 產品簡介:Humira
  • 產品簡介:Pentasa
  • 產品簡介:Remicade
  • 產品簡介:Tysabri

開發平台:克隆氏症

  • 摘要整理
  • 臨床實驗平台:概要

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5415

Disease Overview

Crohn's disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon. Because Crohn's disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active. Crohn's disease is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.

Market Snapshot

Stelara is set to become the leading brand in Crohn's disease as the longstanding anti-TNFs face biosimilar competition.

Infliximab - Remicade and its biosimilar versions - remains the most frequently prescribed biologic by surveyed physicians.

Crohn's disease is an expanding global health problem, with prevalent cases forecasted to increase in the majority of analyzed countries.

Gastroenterologists intend to prescribe Stelara over Entyvio due to its faster onset of action and comparable safety.

Mongersen's oral formulation and favorable safety will drive prescribing, despite its overall modest efficacy to date.

CONTENTS

10 FORECAST: CROHN'S DISEASE

10 Executive Summary

11 Market Overview and Trends

19 Market Definition and Methodology

27 Cimzia (certolizumab pegol)

32 Cx601

37 Entyvio (vedolizumab)

45 etrolizumab

48 filgotinib

53 Humira (adalimumab)

59 mongersen (GED 0301)

63 Remicade (infliximab)

69 Stelara (ustekinumab)

75 Tysabri (natalizumab)

80 Primary Research Methodology

83 TREATMENT: CROHN'S DISEASE

83 Executive Summary

84 Primary Research Methodology

86 Patient Segmentation

89 Current Treatment Options

98 Prescribing Trends

116 Compliance

119 Unmet Needs in Crohn's Disease

123 Prescribing Influences

127 Impact of Biosimilars

135 EPIDEMIOLOGY: CROHN'S DISEASE

135 Executive Summary

136 Disease Background

141 Sources and Methodology

160 Forecast

171 Epidemiologist Insight

179 Strengths and Limitations

185 Appendix

186 MARKETED DRUGS: CROHN'S DISEASE

186 Executive Summary

187 Product Overview

189 Product profile: Cimzia

202 Product profile: Entyvio

216 Product profile: Humira

231 Product profile: Remicade

244 Product profile: Stelara

256 Product profile: Tysabri

265 PIPELINE: CROHN'S DISEASE

265 Executive Summary

266 Clinical Pipeline Overview

267 Comparator Therapy

275 Product profile (late stage): Cx601

287 Product profile (late stage): etrolizumab

295 Product profile (late stage): filgotinib

305 Product profile (late stage): mongersen

LIST OF FIGURES

  • 11 Figure 1: Crohn's disease sales across the US, Japan, and five major EU markets, by country, 2016-25
  • 12 Figure 2: Crohn's disease sales across the US, Japan, and five major EU markets, by class, 2016-25
  • 13 Figure 3: Sales of Humira, Remicade, and their biosimilar versions in the US, Japan, and five major EU markets, 2016-25
  • 15 Figure 4: Sales of Stelara, key branded anti-TNFs, and Entyvio in the US, Japan, and five major EU markets, 2016-25
  • 17 Figure 5: Forecast sales of late-phase therapies in Crohn's disease across the US, Japan, and five major EU markets, 2016-25
  • 22 Figure 6: Datamonitor Healthcare's Crohn's disease forecast methodology
  • 24 Figure 7: Price sources and calculations, by country
  • 29 Figure 8: Cimzia sales in Crohn's disease across the US, Japan, and Spain, by country, 2016-25
  • 34 Figure 9: Cx601 sales in Crohn's disease across the US and five major EU markets, by country, 2016-25
  • 41 Figure 10: Entyvio sales in Crohn's disease across the US, Japan, and five major EU markets, by country, 2016-25
  • 46 Figure 11: Etrolizumab sales in Crohn's disease across the US and five major EU markets, by country, 2016-25
  • 50 Figure 12: Filgotinib sales for Crohn's disease in the US and five major EU markets, 2016-25
  • 56 Figure 13: Humira sales in Crohn's disease across the US, Japan, and five major EU markets, by country, 2016-25
  • 61 Figure 14: Mongersen sales in Crohn's disease across the US and five major EU markets, by country, 2016-25
  • 66 Figure 15: Remicade sales in Crohn's disease across the US, Japan, and five major EU markets, by country, 2016-25
  • 72 Figure 16: Stelara sales in Crohn's disease across the US, Japan, and five major EU markets, by country, 2016-25
  • 77 Figure 17: Tysabri sales in Crohn's disease in the US, 2016-25
  • 87 Figure 18: Severity of diagnosed Crohn's disease patients, by country
  • 98 Figure 19: Mean percentage of Crohn's disease patients receiving pharmacological therapy or non-pharmacological therapy only, by country
  • 105 Figure 20: Mean percentage use of systemic and non-systemic corticosteroids in the US, Japan, and five major EU markets, by line of therapy
  • 106 Figure 21: Mean percentage of drug-treated Crohn's disease patients receiving monotherapy versus combination therapy, by line of therapy
  • 108 Figure 22: Mean percentage of drug-treated Crohn's disease patients receiving anti-TNF therapy, by country and line of therapy
  • 110 Figure 23: Mean percentage use of biologic therapies for the treatment of drug-treated Crohn's disease patients, by biologic and line of therapy
  • 117 Figure 24: Mean compliance rates for drug-treated Crohn's disease patients, by formulation type
  • 120 Figure 25: Top treatment challenges in Crohn's disease
  • 131 Figure 26: Summary of future usage of biosimilar infliximab at one year and three years post-launch
  • 133 Figure 27: Physician confidence in prescribing biosimilars for Crohn's disease approved on the basis of indication extrapolation, by country
  • 163 Figure 28: Trends in diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets, by country, 2015-35
  • 164 Figure 29: Absolute growth of diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets, by country, 2015-35
  • 168 Figure 30: Male diagnosed prevalent Crohn's disease cases in each age group in the US, Japan, and five major EU markets, by country, 2015
  • 169 Figure 31: Female diagnosed prevalent Crohn's disease cases in each age group in the US, Japan, and five major EU markets, by country, 2015
  • 188 Figure 32: Datamonitor Healthcare's drug assessment summary for Crohn's disease
  • 197 Figure 33: Cimzia for Crohn's disease - SWOT analysis
  • 198 Figure 34: Datamonitor Healthcare's drug assessment summary of Cimzia in Crohn's disease
  • 199 Figure 35: Datamonitor Healthcare's drug assessment summary of Cimzia in Crohn's disease
  • 211 Figure 36: Entyvio for Crohn's disease - SWOT analysis
  • 212 Figure 37: Datamonitor Healthcare's drug assessment summary of Entyvio in Crohn's disease
  • 213 Figure 38: Datamonitor Healthcare's drug assessment summary of Entyvio in Crohn's disease
  • 225 Figure 39: Humira for Crohn's disease - SWOT analysis
  • 226 Figure 40: Datamonitor Healthcare's drug assessment summary of Humira in Crohn's disease
  • 227 Figure 41: Datamonitor Healthcare's drug assessment summary of Humira in Crohn's disease
  • 238 Figure 42: Remicade for Crohn's disease - SWOT analysis
  • 239 Figure 43: Datamonitor Healthcare's drug assessment summary of Remicade in Crohn's disease
  • 240 Figure 44: Datamonitor Healthcare's drug assessment summary of Remicade in Crohn's disease
  • 251 Figure 45: Stelara for Crohn's disease - SWOT analysis
  • 252 Figure 46: Datamonitor Healthcare's drug assessment summary of Stelara in Crohn's disease
  • 253 Figure 47: Datamonitor Healthcare's drug assessment summary of Stelara in Crohn's disease
  • 261 Figure 48: Tysabri for Crohn's disease - SWOT analysis
  • 262 Figure 49: Datamonitor Healthcare's drug assessment summary of Tysabri in Crohn's disease
  • 263 Figure 50: Datamonitor Healthcare's drug assessment summary of Tysabri in Crohn's disease
  • 281 Figure 51: Cx601 for Crohn's disease - SWOT analysis
  • 282 Figure 52: Datamonitor Healthcare's drug assessment summary of Cx601 in Crohn's disease
  • 283 Figure 53: Datamonitor Healthcare's drug assessment summary of Cx601 in Crohn's disease
  • 291 Figure 54: Etrolizumab for Crohn's disease - SWOT analysis
  • 292 Figure 55: Datamonitor Healthcare's drug assessment summary of etrolizumab in Crohn's disease
  • 293 Figure 56: Datamonitor Healthcare's drug assessment summary of etrolizumab in Crohn's disease
  • 300 Figure 57: Filgotinib for Crohn's disease - SWOT analysis
  • 301 Figure 58: Datamonitor Healthcare's drug assessment summary of filgotinib in Crohn's disease
  • 302 Figure 59: Datamonitor Healthcare's drug assessment summary of filgotinib in Crohn's disease
  • 311 Figure 60: Mongersen for Crohn's disease - SWOT analysis
  • 312 Figure 61: Datamonitor Healthcare's drug assessment summary of mongersen in Crohn's disease
  • 313 Figure 62: Datamonitor Healthcare's drug assessment summary of mongersen in Crohn's disease

LIST OF TABLES

  • 20 Table 1: Summary of key classes and brands and molecules included in Datamonitor Healthcare's Crohn's disease patientbased forecast
  • 25 Table 2: Exchange rates used for calculating prices
  • 28 Table 3: Datamonitor Healthcare's price assumptions for Cimzia
  • 30 Table 4: Cimzia sales in Crohn's disease across the US, Japan, and Spain, by country ($m), 2016-25
  • 35 Table 5: Cx601 sales in Crohn's disease across the US and five major EU markets, by country ($m), 2016-25
  • 40 Table 6: Datamonitor Healthcare's price assumptions for Entyvio
  • 42 Table 7: Entyvio sales in Crohn's disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 47 Table 8: Etrolizumab sales in Crohn's disease across the US and five major EU markets, by country ($m), 2016-25
  • 51 Table 9: Filgotinib sales in Crohn's disease across the US and five major EU markets, by country ($m), 2016-25
  • 55 Table 10: Datamonitor Healthcare's price assumptions for Humira
  • 57 Table 11: Humira sales in Crohn's disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 62 Table 12: Mongersen sales in Crohn's disease across the US and five major EU markets, by country ($m), 2016-25
  • 65 Table 13: Datamonitor Healthcare's price assumptions for Remicade
  • 67 Table 14: Remicade sales in Crohn's disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 71 Table 15: Datamonitor Healthcare's price assumptions for Stelara
  • 73 Table 16: Stelara sales in Crohn's disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • 76 Table 17: Datamonitor Healthcare's price assumptions for Tysabri
  • 78 Table 18: Tysabri sales in Crohn's disease in the US ($m), 2016-25
  • 80 Table 19: Gastroenterologists surveyed for the Crohn's disease primary research study, 2016
  • 84 Table 20: Gastroenterologists surveyed for the Crohn's disease primary research study, 2016
  • 90 Table 21: Treatment guidelines: initial treatment of active Crohn's disease, by severity
  • 94 Table 22: Treatment guidelines: maintenance of medically induced remission of Crohn's disease and other therapy recommendations
  • 96 Table 23: Summary of key classes and products included in Datamonitor Healthcare's Crohn's disease survey
  • 99 Table 24: Crohn's disease patients receiving pharmacological therapy or non-pharmacological therapy only, by country
  • 101 Table 25: Mean percentage of drug-treated Crohn's disease patients receiving each drug class, by line of therapy and country (%)
  • 107 Table 26: Mean percentage of drug-treated Crohn's disease patients receiving monotherapy or combination therapy, by line of therapy and country (%)
  • 112 Table 27: Mean percentage of drug-treated Crohn's disease patients receiving each biologic therapy, by line of therapy and country (%)
  • 118 Table 28: Compliance rates for Crohn's disease patients, by formulation type and country (%)
  • 119 Table 29: Relative importance of treatment challenges in Crohn's disease, by country
  • 124 Table 30: Relative importance of factors that influence gastroenterologists' prescription of biologics and aminosalicylates in Crohn's disease, by country
  • 128 Table 31: Initial usage of biosimilar infliximab, according to respondents using biosimilar infliximab at the time of the survey, by country (%)
  • 129 Table 32: Expected usage of biosimilar infliximab, according to respondents who did not prescribe biosimilar infliximab at the time of the survey, by country (%)
  • 137 Table 33: Inflammatory bowel disease risk factors
  • 138 Table 34: Montreal classification of Crohn's disease
  • 142 Table 35: Sources used for Crohn's disease analysis in the US, Japan, and five major EU markets
  • 146 Table 36: Notable sources not used for Crohn's disease analysis in the US, Japan, and five major EU markets
  • 148 Table 37: Summary of Crohn's disease data processing in the US, Japan, and five major EU markets
  • 161 Table 38: Diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets, by country, 2015-35
  • 166 Table 39: Age- and gender-specific diagnosed prevalent cases of Crohn's disease in the US, Japan, and five major EU markets, by country, 2015
  • 174 Table 40: Phenotypic distribution of Crohn's disease at diagnosis, by Montreal classification and country, 2015
  • 187 Table 41: Key marketed drugs for Crohn's disease
  • 190 Table 42: Cimzia drug profile
  • 192 Table 43: Cimzia pivotal trial data in Crohn's disease
  • 195 Table 44: Cimzia late-phase trial data in Crohn's disease
  • 203 Table 45: Entyvio drug profile
  • 205 Table 46: Entyvio pivotal trial data in Crohn's disease
  • 208 Table 47: Entyvio ongoing late-phase clinical trials in Crohn's disease
  • 217 Table 48: Humira drug profile
  • 219 Table 49: Humira pivotal trial data in adult Crohn's disease
  • 221 Table 50: Humira pivotal trial data in pediatric Crohn's disease
  • 223 Table 51: Humira ongoing trials in Crohn's disease
  • 232 Table 52: Remicade drug profile
  • 234 Table 53: Remicade pivotal trial data in adult Crohn's disease
  • 237 Table 54: Remicade pivotal trial data in pediatric Crohn's disease
  • 245 Table 55: Stelara drug profile
  • 247 Table 56: Stelara pivotal trial data in Crohn's disease
  • 257 Table 57: Tysabri drug profile
  • 259 Table 58: Tysabri pivotal trial data in Crohn's disease
  • 266 Table 59: Late-phase pipeline products in development for Crohn's disease
  • 268 Table 60: Remicade drug profile
  • 270 Table 61: Remicade pivotal trial data in adult Crohn's disease
  • 274 Table 62: Remicade pivotal trial data in pediatric Crohn's disease
  • 276 Table 63: Cx601 drug profile
  • 278 Table 64: Cx601 Phase III trials in Crohn's disease
  • 280 Table 65: Cx601 Phase I/II trials in Crohn's disease
  • 288 Table 66: Etrolizumab drug profile
  • 289 Table 67: Ongoing pivotal trials for etrolizumab in Crohn's disease
  • 290 Table 68: Other late-phase trials for etrolizumab in Crohn's disease
  • 296 Table 69: Filgotinib drug profile
  • 297 Table 70: Ongoing pivotal Phase III trials of filgotinib in Crohn's disease
  • 299 Table 71: Phase II trial data of filgotinib in Crohn's disease
  • 306 Table 72: Mongersen drug profile
  • 307 Table 73: Pivotal trials for mongersen in Crohn's disease
  • 309 Table 74: Other ongoing Phase III trials for mongersen in Crohn's disease
  • 310 Table 75: Phase II trial data for mongersen in Crohn's disease

 

Back to Top